Researchers and regulators express concerns about the safety of Celebrex and Bextra, fearing heart problems similar to those linked to Vioxx.
Dr. Eric Topol criticizes the FDA for not investigating Vioxx's heart risks earlier.
Merck's decision to withdraw Vioxx raises questions about drug safety monitoring.
FDA's hands-off approach to post-market drug monitoring is criticized.
Suggestions for more thorough, ongoing testing of drugs are made.
Advertising's role in drug prescription is highlighted.
Pfizer warns about Bextra's heart risks in surgery patients.
The withdrawal of Vioxx prompts scrutiny of drug safety assessment processes.
